Breastfeeding After Romiplostim (Nplate) Injection
There is no established waiting period after romiplostim injection before initiating breastfeeding, as the FDA label does not provide specific lactation data or recommendations regarding timing of breastfeeding resumption.
Key Information from FDA Drug Label
The FDA prescribing information for Nplate does not include specific guidance on:
- Transfer of romiplostim into human breast milk
- Effects on the breastfed infant
- Effects on milk production
- Recommended waiting periods before breastfeeding 11
Clinical Reasoning
Pharmacologic Considerations
Romiplostim is a large protein molecule (approximately 59 kDa molecular weight) that:
- Is administered subcutaneously with weekly dosing
- Has pharmacokinetics that make transfer into breast milk theoretically minimal
- Would likely be degraded in the infant's gastrointestinal tract if ingested, given its protein structure
Available Safety Data
The Pregnancy Surveillance Program (2017-2020) documented 186 women exposed to romiplostim during pregnancy, with no specific safety concerns identified for mothers, fetuses, or infants 2. However, this study did not specifically address breastfeeding or lactation timing.
One case report described romiplostim use at 35 weeks gestation with successful delivery, but did not provide breastfeeding information 3.
Practical Recommendation
Given the absence of specific contraindications and the large molecular size of romiplostim making significant breast milk transfer unlikely, breastfeeding can be initiated without a mandatory waiting period after injection.
Important Caveats
- Shared decision-making is essential: Discuss the lack of specific lactation data with the patient
- Monitor the infant: Watch for any unexpected symptoms, though theoretical risk is low
- Document the decision: Given off-label nature of this guidance
- Consider individual factors: Severity of maternal ITP, platelet counts, bleeding risk, and availability of alternative feeding options
Common Pitfall to Avoid
Do not automatically defer breastfeeding for extended periods based solely on medication administration timing when dealing with large protein biologics that have minimal oral bioavailability and unlikely breast milk transfer. The theoretical risk must be balanced against the known benefits of breastfeeding.